226881-06-7

Basic information

• Product Name: 1-(4-Chlorophenyl)-2-oxopyrrolidine-3-carboxylic acid
• Synonyms: 3-Pyrrolidinecarboxylic acid, 1-(4-chlorophenyl)-2-oxo-
• CAS NO: 226881-06-7
• Molecular Formula: C₁₁H₁₀ClNO₃
• Molecular Weight: 239.65
• Mol File: 226881-06-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(4-Chlorophenyl)-2-oxopyrrolidine-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-Chlorophenyl)-2-oxopyrrolidine-3-carboxylic acid(226881-06-7)
• EPA Substance Registry System: 1-(4-Chlorophenyl)-2-oxopyrrolidine-3-carboxylic acid(226881-06-7)

Safety Data

• Hazardous Substances Data: 226881-06-7(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
1-(4-Chlorophenyl)-2-oxopyrrolidine-3-carboxylic acid is used as a reactant in chemical synthesis for its ability to contribute to the formation of various complex molecules. Its reactivity and structural properties make it a valuable component in creating a diverse array of chemical products.
Used in Organic Chemistry:
In the field of organic chemistry, 1-(4-Chlorophenyl)-2-oxopyrrolidine-3-carboxylic acid is used as a building block to construct more intricate organic molecules. Its presence in molecular structures can influence the physical and chemical properties of the final products, making it an essential compound in organic synthesis.
Used in Pharmaceutical Chemistry:
1-(4-Chlorophenyl)-2-oxopyrrolidine-3-carboxylic acid is also utilized in pharmaceutical chemistry as a key component in the development of new drugs. Its integration into drug molecules can enhance their efficacy, selectivity, and other pharmacological properties, contributing to the advancement of medicinal chemistry.
Used in Biochemical Applications:
1-(4-Chlorophenyl)-2-oxopyrrolidine-3-carboxylic acid finds application in biochemical research, where it can be employed to study enzyme mechanisms, develop new biochemical assays, or understand the interactions between biological molecules. Its solubility and reactivity make it a suitable candidate for exploring various biochemical processes.

Upstream product

• 5617-70-9 cycl-isopropylidene cyclopropane-1,1-dicarboxylate 
• 106-47-8 4-chloro-aniline 
• 171054-81-2 1-(4-chlorophenyl)-3-ethoxycarbonyl-2-pyrrolidinone 

Downstream Products

• 133748-91-1 1-(4-chlorophenyl)-3-hydroxymethylpyrrolidine 
• 1207473-51-5 1-(4-chlorophenyl)-5-chloropyrrole-2,4-dicarbaldehyde 
• 88075-88-1 1-(4-chlorophenyl)-1H-pyrrole-3-carbaldehyde 

Relevant articles and documents

Discovery of novel dual c-Met/HDAC inhibitors as a promising strategy for cancer therapy

Owing to the low efficacy and acquired resistance in clinical trials of c-Met inhibitors, based on the synergistic effects between c-Met and HDAC, novel c-Met and HDAC dual inhibitors were designed and synthesized. We introduced 2-pyrrolidinone to form the 5-atoms linker for c-Met inhibitor and hydroxamic acid as a zinc binding motif for HDAC inhibitor. The highly active dual inhibitor 15f showed excellent and balanced activity against both c-Met (IC50 = 12.50 nM) and HDAC1 (IC50 = 26.97 nM). In those tested tumor cell lines, 15f exhibits efficient antiproliferative activity with greater potency than Vorinostat (SAHA) and Cabozantinib (XL184). However, by comparing with an equimolar mixture of SAHA and Foretinib, we did not observe the compounds showed clearly synergistic antiproliferative effect. Nevertheless, compound 15f was found to induce apoptosis and cause cell cycle arrest in G2/M phase. This proof-of-concept study provides an efficient strategy for discovery of multitarget antitumor drugs.

INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES

This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

Sodium borohydride-iodine mediated reduction of γ-lactam carboxylic acids followed by DDQ mediated oxidative aromatisation: a simple approach towards N-aryl-formylpyrroles and 1,3-diaryl-formylpyrroles

A simple methodology for the conversion of substituted N-aryl-γ-lactam 2/3-carboxylic acids to substituted N-aryl-2/3-formyl-pyrroles has been developed. Several N-aryl-γ-lactam 2/3-carboxylic acids were reduced to substituted (N-aryl-pyrroliden-2/3-yl)-m

Method for production of pyrrolidinone derivatives

A compound represented by the following formula (12) useful as an intermediate for production of drug or agricultural chemical: (wherein R21to R25are each independently a hydrogen atom, a hydroxyl group, a halogen atom, an alkyl grou